The companies plan to combine their world-leading expertise in the development of new excipients and drug formulations to provide customers from the pharmaceutical industry with early access to the latest polymer innovations. The aim of this collaboration is to meet increasing challenges of poorly soluble active pharmaceutical ingredients (BCS Class II and IV compounds); the initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble active pharmaceutical ingredients.
"We are excited about the opportunities this collaboration brings to us and our customers," said Rod Ray, CEO of Bend Research. "It offers early access to a different set of chemistries and allows us to develop and test customer formulations based on new polymers. BASF has an impressive track record developing and launching novel excipients. This deal complements our recently announced collaboration on cellulosics, because it gives us access to completely different chemistries."
"We are glad to bring our in-depth knowledge of polymeric excipients into this collaboration to jointly extend the current toolbox already comprising innovations like Soluplus®,” said Ralf Fink, Vice President Global Marketing at BASF Pharma Ingredients & Services business unit. “Coupled with Bend Research’s outstanding strengths in formulation development, including spray-drying and hot-melt extrusion, we are in a unique position to address urgent solubility challenges. With this partnership, we help our customers with the development of drugs with poor bioavailability."
BASF has extensive ingredient formulation and material science expertise, as well as world-class excipient products. Bend Research is the leading formulation development and technology firm in the field of spray drying and has recently expanded capabilities in hot-melt extrusion.
BASF (basf.com) is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success, social responsibility and environmental protection. Through science and innovation we enable our customers in almost all industries to meet the current and future needs of society. Our products and system solutions contribute to conserving resources, ensuring healthy food and nutrition and helping to improve the quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF posted sales of about €73.5 billion in 2011 and had more than 111, 000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN).
About Bend Research Inc.
For more than 35 years, Bend Research Inc. has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding. Bend Research Inc. provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies. With more than 285 employees, Bend Research Inc. is based in six state-of-the-art facilities in Bend, Oregon, USA.
Bend Research Press Contact:
Phoenix Barringer, Bend Research Inc.
P: +1 541-382-4100 - E: phoenix.barringer[.]bendresearch.com.